• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Bactroban Dermal
    / GSK


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Ointment

    15 gr

    partial basket chart 20699 2352

    Dosage

    Adults (including elderly/hepatically impaired) and children: Two to three times a day for up to ten days, depending on the response.   A small quantity of Mupirocin should be applied to cover the affected area. The treated area may be covered by a dressing.  Any product remaining at the end of treatment should be discarded. Do not mix with other preparations as there is a risk of dilution, resulting in a reduction of the antibacterial activity and potential loss of stability of the mupirocin in the ointment.


    Indications

    Mupirocin is a topical antibacterial agent, active against those organisms responsible for the majority of skin infections. Mupirocin is used for skin infections, e.g. impetigo, folliculitis, furunculosis.


    Contra-Indications

    Hypersensitivity to mupirocin or any of the excipients. This formulation is not suitable for ophthalmic or intranasal use.     


    Special Precautions

    Should a possible sensitisation reaction or severe local irritation occur with the use of Mupirocin, treatment should be discontinued, the product should be washed off and appropriate therapy instituted. As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms. Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhea during or after antibiotic use. Although this is less likely to occur with topically applied mupirocin, if prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.
    Renal impairment: Elderly Patients: No restrictions unless the condition being treated could lead to absorption of polyethylene glycol and there is evidence of moderate or severe renal impairment.
    Mupirocin is not suitable for: ophthalmic use intranasal use (in neonates or infants) use in conjunction with cannulae at the site of central venous cannulation. For intranasal use, a separate presentation, Bactroban nasal ointment, is available. Avoid contact with the eyes. If contaminated, the eyes should be thoroughly irrigated with water until the ointment residues have been removed. Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol based ointments, Bactroban Dermal should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.


    Side Effects

    Skin and subcutaneous tissue disorders: Common: Burning localised to the area of application. Uncommon: Itching, erythema, stinging and dryness localised to the area of application. Uncommon: Cutaneous sensitisation reactions to mupirocin or the ointment base.
    See prescribing information for full details.


    Drug interactions

    No drug interactions have been reported.


    Pregnancy and Lactation

    Pregnancy: Mupirocin should only be used in pregnancy when the potential benefits outweigh the possible risks of treatment.
    Lactation: There is no information on the excretion of Mupirocin in milk. If a cracked nipple is to be treated, it should be thoroughly washed prior to breast feeding.
    See prescribing information for full details.


    Overdose

    The toxicity of Mupirocin is very low. In the event of accidental ingestion of the ointment symptomatic treatment should be given. In case of erroneous oral intake of large quantities of the ointment, renal function should be closely monitored in patients with renal insufficiency because of the possible side effects of polyethylene glycol.


    Manufacturer
    Glaxo Operations UK Ltd
    CLOSE